05/28/2026
New laser heat treatment could stop blindness before it starts!
Researchers have developed a new heat-based treatment that could help stop dry macular degeneration by activating the eye’s natural repair systems. Credit: Shutterstock
Age related macular degeneration (AMD) affects an enormous number of older adults. Around one third of people over 80 have AMD, and about 20 million Americans age 40 and older are living with the condition.
Most cases are the dry form of AMD. It usually advances gradually, but over time it can damage central vision, making it harder to see faces, read, drive, or focus on objects straight ahead. Despite how common dry AMD is, doctors still have limited options for stopping it early.
A study from Aalto University points to a different strategy. Instead of trying to replace damaged cells after vision loss has advanced, researchers are exploring whether they can help vulnerable eye cells defend and repair themselves before the disease causes severe damage.
The approach uses carefully controlled heat delivered with near infrared light. The goal is to gently warm tissue at the back of the eye just enough to activate natural repair systems, without causing harm.
Helping Aging Eye Cells Fight Back
Professor Ari Koskelainen says the idea is to strengthen the protective machinery inside affected cells.
"Cellular functionality and protective mechanisms weaken with age, which exposes the fundus [the inside surface at the back of the eye] to intense oxidative stress," he explains. "Free oxygen radicals damage proteins, which causes them to misfold and aggregate, then fatty protein deposits called drusen begin to accumulate, which is the main diagnostic criterion for the dry form of age-related macular degeneration."
Those fatty protein deposits, known as drusen, are a major warning sign of dry AMD. As they build up, they can interfere with the health of the retina, especially the macula, the part of the eye responsible for sharp central vision.
The Aalto team's method is designed for the early diagnosis phase, when there may still be time to slow or potentially halt the disease process. That is the key reason the work has drawn attention. It targets the damage before it becomes devastating.
Why Heat Could Help
Using heat in the retina is not simple. The tissue must be warmed by only a few degrees, and the back of the eye is difficult to measure directly. If the temperature climbs above 45 degrees Celsius, tissue damage can occur.
To solve that problem, the researchers developed a system that can heat the tissue with near infrared light while monitoring temperature at the same time. That real time control is central to the approach, because the treatment depends on staying within a safe and useful range.
The heat is not meant to burn or destroy tissue. Instead, it works more like a controlled stress signal. By giving cells a mild heat shock, the researchers hope to trigger protective responses that become weaker with age.
One of those responses involves heat shock proteins. These proteins are produced when cells are under stress, and they can help damaged proteins fold back into the correct shape. If repair is not possible, the faulty proteins are usually broken down into amino acids so the cell can reuse or remove them.
Turning On the Cell's Cleanup System
If damaged proteins have already clumped together, another process becomes important. It is called autophagy, and Yoshinori Ohsumi received the Nobel Prize in Medicine in 2016 for discoveries related to it.
Autophagy acts like a cellular cleanup system. A membrane forms around unwanted material, and recognition proteins help guide enzymes that break down old or damaged components. In dry AMD, that kind of cleanup could matter because protein deposits and cellular stress are central features of the disease.
"We were able to show that we can activate not only the production of the heat shock proteins, but also autophagy using the heat shocks. This process is like waste disposal," says Koskelainen.
That makes the treatment especially intriguing. It is not just aimed at one symptom. It attempts to revive two basic survival systems that cells use to repair damage and clear out harmful material.
Promising Results Before Human Testing
The method has been tested in mice and pigs. In those animal studies, the researchers showed that controlled heating could activate the desired protective response in retinal tissue.
The next major step is human testing. Patient trials are planned to begin in Finland in spring 2026. The first stage will focus on safety, not on proving that the treatment improves vision or stops AMD progression. If that phase goes well, researchers hope to learn how often the procedure would need to be repeated.
"The treatment needs to be repetitive, since the response can already begin to decline some days after the treatment," Koskelainen says.
That detail is important. The treatment may not be a one time fix. If it works in people, it could become more like a maintenance therapy, repeated at intervals to keep the eye's protective systems active.
A Fast Moving Field for Dry AMD
The Aalto approach is part of a broader shift in dry AMD research. For years, dry AMD was often described as a condition with few meaningful treatment options, especially in earlier stages. That is beginning to change.
In the US, the FDA has authorized Valeda Light Delivery System, a different light based device for selected patients with dry AMD. Unlike the Aalto treatment, Valeda uses photobiomodulation rather than controlled retinal heating. FDA documents describe it as a prescription device intended to improve visual acuity in patients with certain forms of dry AMD and without center involving geographic atrophy or neovascular maculopathy.
That does not mean the Aalto treatment is already proven in patients. It remains experimental until human trial data show whether it is safe and effective. But it does place the research in a field where light based therapies are gaining serious attention.
From Lab Discovery to Eye Clinics
The Aalto study was published in Nature Communications on October 29, 2025. Researchers are also working to commercialize the technology through a research to business startup called Maculaser.
"An optimistic schedule would see the method already being used in hospital eye clinics in as little as three years' time," says Koskelainen. "The eventual goal is that it would be readily available at your local ophthalmologist."
For now, the promise is still ahead of the proof. The treatment has worked in animal models, and the first human trials are intended to establish safety. But if future studies confirm the early results, a carefully controlled burst of laser heat could become a new way to help aging eyes protect themselves before vision loss takes hold.
